Rapid Hybridoma Screening with Automated Sample Preparation and Digital SPR Analysis

Béatrice Sacripanti, Associate Director of Product Development, Nicoya Lifesciences

Introduction

Alto[™] is the world's only Digital SPR[™] instrument that uses digital microfluidics (DMF) to handle samples. This allows all SPR sensors, samples, buffers and reagents needed for an experiment to be contained in a disposable, automation-compatible cartridge, making Alto the only fully

automatable SPR instrument.

Here, we show how Alto seamlessly integrates with the Opentrons Flex[™] and Brooks Automation PF400 robot arm to rapidly screen through hybridomas in supernatant with only a few minutes of user intervention.

Nicoya's analysis software automatically analyzes the data from each interaction to identify and provide single concentration kinetics on hits.

Alto[™] Digital SPR[™]: Label-free binding analysis in a droplet

Nicoya's Alto system uses digital microfluidics (DMF) to deliver automatically diluted sample droplets to SPR sensors for effortless real-time characterization of biomolecular interaction analysis including quantitation, screening, epitope binning and binding kinetics.



Sensor

Sample

- 16 independently addressable channels for high throughput.
- Complete kinetics analysis using only 2 µL of crude or purified sample.
- No manual dilutions, tagging, degassing, cleaning, or strenuous assay set up.
- Powerful screening data visualization and analysis software.

What is DMF? (Digital Microfluidics)

DMF is a liquid-handling technology capable of accurately controlling and manipulating discrete nanoliter-sized droplets across an array of electrodes. The fluidics are contained within a disposable cartridge, allowing Alto to overcome the major limitations associated with increasingly complex fluidic systems present in traditional label-free instruments.

Automated Cartridge Preparation

Traditional SPR instruments are difficult to automate due to their complex and error-prone fluidic systems. Any error with the fluidics within the scheduled runs can be detrimental for subsequent assays, particularly when using crude samples.

Alto's cartridge-based fluidics overcome these issues and make it an ideal SPR instrument for screening and automation integration. Operating as an integrated workcell, Nicoya's Alto, the Opentrons Flex and the Brooks PF400 robot arm enable rapid, hands-free screening of up to 2,000 leads/week.

A A

Figure 1 shows how the Alto Automation Suite can be configured to screen through over 200 hybridoma leads in crude sample in 32 hours.

> Figure 1: A) Diagram showing the different components of the automated Alto workcell.

Hybridoma Screening

Real-time, label-free binding analysis is routinely used to screen hybridoma clones for high affinity antibodies prior to further expansion and subsequent characterization. Alto allows for rapid, automated, SPR-quality screening and characterization of biologic lead libraries with simple, pre-configured capture screening and binding kinetics characterization assays to select lead molecules.

Figure 2 shows the capture screening assay, where an anti-human VHH was immobilized to the sensor surface. The hybridomas were used as ligands, with their target, H5N1 Hemagglutinin (HA), as the analyte.



Antibodies generating binding responses greater than 40 RUs were considered hits, and those with responses below 20 RUs are non-binders. Anything in between were considered intermediate binders.



Figure 2: B) Sample sensorgram showing binding of the target to one of the captured mAbs showing a hit.

Figure 2: A) Grid view of all the binding curves measured between each antibody (ligand) and H5N1 HA. The 12 hits are highlighted in green, while the 4 intermediate hits are highlighted in yellow. Other interactions did not generate a sufficient binding response and are considered non-binders.

50 51 52	10-	30	50
	20 832 000 200 400 522 000 200 400 520		
300 400 500 000 200 400 000 200 40		000 200 400 600 100 200 400 500 000	212 400 512 100 210 400 510 100
34 3 3 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0	0	
200 402 000 500 200 422 001 500 200 4	ass an mi the sis an mi the sis	326 003 me 207 528 033 me 607 568	210 400 600 650 270 402 600 670
8 8 9	50		mm
250 132 000 550 200 155 003 500 200 1		301 201 100 EU 301 200 100 EU 400	230 100 800 800 200 100 800
39	30-	50	м — — — — — — — — — — — — — — — — — — —
50	10 20	20 20	50 50
a a		- U U	U U
20 432 600 100 200 422 603 100 40	20 103 104 105 105 105 105 105 105 105 105 105	000 200 400 200 000 200 400 200 000	200 440 000 000 200 400 000 500
3	10- 0- 0-	50- 50-	m
	10 GAS 8000 200 403 GAA 400 200 400 GAA	8200 202 400 2060 425 202 400 500 650	200 433 600 600 200 435 603 800
99	30		n
0 200 122 003 E00 201 003 E00 102 200 1		000 200 100 100 000 200 100 100 100 000	
22	20 20	50	w w
s s s		0	a and a many
200 400 000 800 200 400 000 800 200 4	16 633 800 - 200 400 635 800 - 200 400 635	ana 200 400 220 ano 200 400 200 ano	320 433 (20 ALO 720 433 200 820
32- 0	20 20- 0	50- 0 - 50-	50 50
210 107 000 210 120 000 200 1	10 0.77 NOU 2001 110 0.75 NOU 2003 100 850	201 201 400 500 400 200 400 500	237 400 937 800 200 407 800 800
37		30	N
52 52 52	30 50	30 30	50
a	v v		u u
	00 633 600 200 400 500 000 200 400 500	000 200 400 500 000 <u>200 400 500 500</u>	200 400 600 500 200 400 600 500
53 51 52 52 55 55 55 55 55 55 55 55 55 55 55	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		
200 435 min sin 200 428 min sin 200 4	asa nin ing asa nin nin asa	and the ran and and the second s	336 400 600 600 700 400 600 600
79- 57- 57- 57- 57- 57- 57- 57- 57- 57- 57	50- 0		n n
210 135 000 280 280 156 033 800 200 1		810 201 400 kto 400 200 kto eto	200 100 600 200 100 800
50-50-50-50-50-50-50-50-50-50-50-50-50-5	30-	50-	50- 50-
50 51 52	30 20	20 20	50 50
at a start at the start of the	U		U
200 432 000 200 420 000 200 4	00 632 8000 2000 4000 500 803 200 400 500	ata 200 400 550 800 200 400 500 800	320 433 660 850 750 433 660 550
53-	50- 50-	50 50	57. 57. 0 0
250 432 cm 550 20 425 cm 960 20 4	16 612 800 700 400 525 800 700 400 500	au 200 em con au 200 em con au	250 933 600 850 250 435 603 800
a a a			n
210 137 000 200 100 110 001 120			
39	20-	50	50-
			220 400 600 500 220 400 600 000
2	50 50 D	20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
200 402 000 EE0 200 402 000 EE0 200 4	20 r33 r00 - 200 400 520 000 - 203 400 520	202 202 400 550 002 202 400 550 020	202 400 022 000 200 403 000 800
	TD	50-0-	31 31
215 400 520 590 200 200 100 500 900 200 100 100 100 100 100 100 100 100 1			
30-30-50-	50-		
at		800	





Figure 1: B) Diagram showing the deck configuration of the **Opentrons Flex for preparation** of hybridoma samples and transfer to Alto cartridge.

- 1. The PF400 robot arm transferred a cartridge from the plate hotel to slot C3 of the Opentrons Flex.
- 2. Using the Opentrons Flex, samples in supernatant were transferred from the hybridoma plate to the 384-well plate and diluted 2x with buffer from the well trough.
- 3. Samples, reagents and buffers were transferred to the Alto Cartridge[™] according to the sample layout .csv file obtained from the User Portal.
- 4. The PF400 transferred the cartridge to the Alto.
- 5. The capture screening assay was initiated on the Alto.
- 6. Once the experiment was completed, the PF400 removed the cartridge from the Alto.

Conclusion

Alto's API and cartridge-based fluidic handling make it the first SPR instrument to be fully compatible with automation. This is demonstrated in this study where the Alto Automation Suite is used to rapidly screen hundreds of antibodies in crude sample.

In this study, 4 cartridges were run to screen over 180 antibodies in 32 hours. Each cartridge was prepared with the Opentrons Flex, and loaded into Alto with the Brooks PF400 robot arm, showing how the Alto Automation Suite[™] takes the human labor and error out of affinity measurements.

The automated workflow demonstrated is a powerful addition to drug discovery labs, enabling screening of thousands of candidates per week with miniman hands-on time.



Learn how Alto can take your discoveries to the next level. Visit our website or contact us: info@nicoyalife.com









